Nebulizers and Accessories
Our unique palladium vibrating mesh technology, Aerogen Vibronic® is a breakthrough in aerosol drug delivery and is at the heart of all our products
As the world leader in acute care aerosol drug delivery, Aerogen have an extensive Intellectual Property Portfolio of more than 300 granted active and pending patents with coverage in multiple countries across the globe.
These patents are held in various Aerogen / Stamford Devices Ltd. Group companies. In addition Aerogen have co-licensed IP agreements with several institutions and MNC’s notably Novartis AG and Philips.
Aerogen uses IP within this portfolio to protect it’s market position, as it enhances the lives of millions of patients in more than 75 countries.
Certain Aerogen R&D initiatives are co-funded by the European Regional Development Fund and Enterprise Ireland as part of the Border, Midland and Western Regional Operational Programme 2014-2020. This R&D aims to develop novel nebulizer systems aimed at increasing R&D activity which will drive company development.
